

Technology Appraisal Committee B Interests Register

**Topic: Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable
ID3981**

Publication Date: 05 September 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Peter Wheatley-Price	TAC Committee Member	Direct- financial	Peter works for Takeda, who manufacture Ixazamib which is used in combination with lenalidomide and dexamethasone in adults who have received at two/three prior therapies. Isatuximab currently have access via CDF (under appeal) in combination with pomalidomide and dexamethasone in the same indication (ID4067).	21/05/2025 07/05/2025	It was agreed that Peter's declaration would prevent him from participating in discussions on this appraisal.
David McAllister	TAC Committee Member	Indirect – non-financial professional	David's research uses clinical trial data provided by Sanofi and Johnson & Johnson (among other sponsors) via the Vivli trial repository	11/06/2025 07/05/2025	It was agreed that David's declaration would not prevent him from participating in discussions on this appraisal.
Mike Chambers	TAC Committee Member	Direct - financial	Mike has provided consulting advice to Sanofi (submitting company) not specific to any disease area, and has participated in an advisory board for Accord (possible comparator company) in an unrelated disease area: Small Cell Lung cancer. Mike	07/05/2025	It was agreed that Mike's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			has participated in an advisory panel for Pfizer (possible comparator company) in an unrelated disease area: prostate cancer		
Jaimal Kothari	Clinical Expert	Indirect - financial	Jaimal has received honoraria (for advisory board membership) in 2024 from Sanofi (manufacturer of Isatuximab), and honoraria from Janssen (the manufacturers of Daratumumab, which is one of the drugs in one of the comparator combinations).	02/07/2025 07/05/2025	It was agreed that Jaimal's declaration would not prevent them from providing expert advice to the committee.
Neil Rabin	Clinical Expert	Indirect - financial	Neil has received advisory board, speaker fees and support to attend educational meetings	02/07/2025 07/05/2025	It was agreed that Neil's declaration would not prevent them from providing expert advice to the committee.
Frankie McGauran	Patient Expert	Indirect - financial	Expert Nominator Myeloma UK received funding from the manufacturer of the technology (Sanofi) in the last 12 months. In 2023, 6% of Myeloma UK's income came from pharmaceutical companies (£295,263).	02/07/2025 07/05/2025	It was agreed that Frankie's declaration would not prevent them from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Caroline Donoghue	Patient Expert	Indirect - financial	Expert Nominator Myeloma UK received funding from the manufacturer of the technology (Sanofi) in the last 12 months. In 2023, 6% of Myeloma UK's income came from pharmaceutical companies (£295,263).	02/07/2025 07/05/2025	It was agreed that Caroline's declaration would not prevent them providing expert advice to the committee.